184 related articles for article (PubMed ID: 15115528)
1. Diffuse cutaneous systemic sclerosis treated with intravenous iloprost.
Foti C; Cassano N; Conserva A; Coviello C; De Meo M; Vena GA
Clin Exp Dermatol; 2004 May; 29(3):321-3. PubMed ID: 15115528
[No Abstract] [Full Text] [Related]
2. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.
Faggioli P; Giani L; Mazzone A
Clin Exp Rheumatol; 2006; 24(2):220-1. PubMed ID: 16762173
[No Abstract] [Full Text] [Related]
3. [Iloprost for the treatment of systemic sclerosis].
Hachulla E; Launay D; Hatron PY
Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
[TBL] [Abstract][Full Text] [Related]
4. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
5. Effects of iloprost on microvascular structure assessed by nailfold videocapillaroscopy: a pilot study.
Shah P; Murray AK; Moore TL; Herrick AL
J Rheumatol; 2011 Sep; 38(9):2079-80. PubMed ID: 21885525
[No Abstract] [Full Text] [Related]
6. Thrombotic events in patients with systemic sclerosis treated with iloprost.
Tedeschi A; Meroni PL; Del Papa N; Salmaso C; Boschetti C; Miadonna A
Arthritis Rheum; 1998 Mar; 41(3):559-60. PubMed ID: 9506585
[No Abstract] [Full Text] [Related]
7. Ischemic finger ulcer as a presenting symptom of systemic sclerosis.
Balbir-Gurman A; Markovits D; Nahir AM; Rozin A; Braun-Moscovici Y
Isr Med Assoc J; 2005 Aug; 7(8):531-2. PubMed ID: 16106783
[No Abstract] [Full Text] [Related]
8. [Iloprost therapy in systemic sclerosis].
Bali G; Aberer E
Hautarzt; 2003 Sep; 54(9):845-51. PubMed ID: 12955262
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
10. Iloprost treatment in systemic sclerosis: comment on the concise communication by Tedeschi et al.
Braun J; Sieper J; Riemekasten G; Hiepe F
Arthritis Rheum; 1999 Jan; 42(1):196-8. PubMed ID: 9920036
[No Abstract] [Full Text] [Related]
11. Is iloprost effective in secondary Raynaud's phenomenon?
Lustig N; Rada G
Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
[TBL] [Abstract][Full Text] [Related]
12. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
14. Vasospasmolytic therapy in patients with SSC.
Jünger M; Schlez A; Klyscz T; Steins A; Hahn M
Adv Exp Med Biol; 1999; 455():305-7. PubMed ID: 10599360
[No Abstract] [Full Text] [Related]
15. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
17. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.
Caramaschi P; Martinelli N; Volpe A; Pieropan S; Tinazzi I; Patuzzo G; Mahamid H; Bambara LM; Biasi D
Clin Rheumatol; 2009 Jul; 28(7):807-13. PubMed ID: 19301062
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.
Wigley FM; Wise RA; Seibold JR; McCloskey DA; Kujala G; Medsger TA; Steen VD; Varga J; Jimenez S; Mayes M; Clements PJ; Weiner SR; Porter J; Ellman M; Wise C; Kaufman LD; Williams J; Dole W
Ann Intern Med; 1994 Feb; 120(3):199-206. PubMed ID: 7506013
[TBL] [Abstract][Full Text] [Related]
19. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
Kamata Y; Kamimura T; Iwamoto M; Minota S
Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
[No Abstract] [Full Text] [Related]
20. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis.
Marczin N; Riedel B; Royston D; Yacoub M
Lancet; 1998 Aug; 352(9125):405-6. PubMed ID: 9717956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
